EMA Steps Up Push for Greater Clinical Trial Transparency

Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.

PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.

Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.

Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

Shionogi’s Dr. Draica on why COVID-19 still matters — and why the window between exposure and symptoms is where XOCOVA can intervene.

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.

Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.